BioClonal presents RedMabs Platform & Real Biobetters at PEGS EUROPE

BioClonal will present RedMabs Platform, the company's innovative platform to generate Real Biobetters, at the Protein & Antibody Engineering Summit (PEGS EUROPE) conference in Barcelona, Spain on November 14, 2022.

Today, Paula Garfella, Business Development Manager at BioClonal, will give an oral presentation from 13:55 till 14:15 introducing BioClonal's Therapeutics Antibody Discovery Platform able to provide a battery of enhanced versions - Real Biobetters -  of any Monoclonal Antibody given. This breakthrough allows  to prolong the effective exclusivity period for 15 years, solving or minimizing the Patent Cliff problem.

BioClonal's  puts forward its poster "Is there a Real Solution for the therapeutic mAbs Patent Cliff?,  an outline of RedMabs features and benefits. 

Details of our presentations are as follows:

Poster A4: Is there a Real Solution for the Therapeutic mAbs Patent Cliff?, Presented by Paula Garfella Lorente.
Stop by our poster and meet Paula Garfella Lorente to learn more about #RealBiobetters and #RedMabsPlatform.
You can also chat online during the VIRTUAL POSTER CHAT (13:55 - 14:15 )
🤝🏼 BioClonal welcomes co-development and partnership inquiries. Interested parties may contact us at bd@bioclonal.es to set up a meeting.
-------------------------------------------------------------------------

💡Not attending #PEGSEurope but want to know more about our technologies? Email at bd@bioclonal.es . Tell us your challenges and our mAbs experts will help you.  

BioClonal is a biotech start up born with the firm mission to bring all our extensive knowledge to the world of monoclonal antibodies. Our business card says we were born to "Empower your monoclonal antibody to the extraordinary". We want to be your strategic partner to improve your monoclonal antibodies. We have a philosophy of long term and win-win relationships.